Reply to Woltsche N. et al. Managing adverse effects by dose reduction during routine treatment of locally advanced basal cell carcinoma with the hedgehog inhibitor vismodegib: a single center experience

Abstract

We read with great interest the article entitled "Managing adverse effects by dose reduction during routine treatment of locally advanced basal cell carcinoma (laBCC) with the hedgehog inhibitor vismodegib: a single center experience" recently published in your journal and we want to report also our experience regarding the effect of dose reduction of hedgehog inhibitor vismodegib treatment as a new therapeutic option in order to reduce the high frequency of adverse events and increase patients compliance.

This article is protected by copyright. All rights reserved.

http://bit.ly/2MPb2Gg